This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cannabis: Archive
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZPositive Net Change PBYINegative Net Change NTLANegative Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRNegative Net Change LAMRPositive Net Change EPRNegative Net Change
cannabis finance marijuana reit
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZPositive Net Change HRMYNegative Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
JAZZPositive Net Change EBSNegative Net Change
biotechs cannabis medical pharmaceuticals
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCNegative Net Change ACBNegative Net Change OGINegative Net Change
cannabis healthcare marijuana marijuana-stocks medical
IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.
RHPNegative Net Change IIPRNegative Net Change PKNegative Net Change
cannabis finance marijuana reit
Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?
by Moumita C. Chattopadhyay
With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?
PLDNegative Net Change TRNONegative Net Change IIPRNegative Net Change
cannabis finance marijuana marijuana-stocks reit
GrowGeneration Earnings Miss Estimates in Q3, Revenues Dip Y/Y
by Zacks Equity Research
GRWG expects revenues between $190 million and $195 million for 2024.
BGPositive Net Change RKDANegative Net Change GRWGNegative Net Change WFGPositive Net Change
basic-materials cannabis earnings
Pre-Markets Soar after Trump Wins U.S. Presidential Election
by Zacks Equity Research
Pre-Markets Soar after Trump Wins U.S. Presidential Election
QCOMNegative Net Change TMNegative Net Change GILDPositive Net Change TSLANegative Net Change TRIPNegative Net Change ACBNegative Net Change COINNegative Net Change ARKBNegative Net Change
auto-tires-trucks biotechs bitcoin blockchain cannabis cryptocurrency etfs semiconductor